Synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.
Methods, pharmaceutical formulations, and kits are provided for using Transient Receptor Potential Vanilloid 1 (TRPV1) agonists to increase rectal pressure and induce defecation in mammals.
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07C 275/36 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
3.
COMPOSITIONS FOR INDUCING URINARY VOIDING AND DEFECATION
Synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary "on-demand" voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07D 207/00 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
4.
COMPOSITIONS AND METHODS FOR TREATING AUTONOMIC DYSREFLEXIA
Compositions and methods are provided to treat, prevent and/or reduce the frequency of autonomic dysreflexia (AD) and/or episodic hypertensive events. The compositions include NK1 receptor antagonists for parenteral or enteral administration to a subject, or pharmaceutically acceptable salts, esters, amides, prodrugs, or derivatives thereof. The NK1 receptor antagonists can selectively block activation of NK1 receptors in the peripheral and central nervous system that give rise to AD. Methods are provided for treating an acute episode of AD in a subject by parenterally administering a therapeutically effective amount of a NK1 receptor antagonist to reduce the severity and/or duration of the AD. In addition, methods are provided for preventing or reducing the frequency and/or severity of AD by administering either parenterally or enterally a therapeutically effective amount of a NK1 receptor antagonist to a subject on a continuous basis, such as twice daily, once daily, or once weekly.
Methods, pharmaceutical formulations, and kits are provided for using capsaicin to effectuate voluntary defecation in mammals who cannot defecate without external invasion of the bowel or those who defecate involuntarily (i.e., those having fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing defecation in mammals that do not have defecation dysfunction such as, for example, in a person who is unconscious and may defecate unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with defecation dysfunction control over when and where they defecate.
Methods, pharmaceutical formulations, and kits are provided for using capsaicin to effectuate voluntary defecation in mammals who cannot defecate without external invasion of the bowel or those who defecate involuntarily (i.e., those having fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing defecation in mammals that do not have defecation dysfunction such as, for example, in a person who is unconscious and may defecate unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with defecation dysfunction control over when and where they defecate.
Eleven synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.
A stimulator device for controlling waste storage for a subject, having one electrode placed in proximity to a portion of each of the right and left pudendal nerves, which contains efferent fibers that, when stimulated, produce contraction of the urethral or anal sphincter. The stimulator device having a pulse generator connected to electrodes, bilaterally, to provide stimulation for each electrode to stimulate pudendal efferent axons. The pulse generator adapted to provide a first type of stimulation to cause waste to be stored within the subject. The pulse generator adapted to provide a second type of stimulation, different from the first type of stimulation, to allow waste to be voided from the subject by blocking nerve impulses that accompany sphincter dyssynergia. An input device to allow an end user to select the first type of stimulation, the second type of stimulation, or no stimulation. Variations of the concept are disclosed.
A stimulator device for use in controlling waste storage for a patient. The stimulator device having a set of at least one electrode placed in proximity to a relevant portion of a pudendal nerve. The stimulator device having a pulse generator connected to the set of at least one electrode to provide stimulation input for use by the electrode to stimulate the pudendal nerve. The pulse generator adapted to provide a first type of stimulation to cause waste to be stored within the patient and to provide a second type of stimulation different from the first type of stimulation. The second type of stimulation allows waste to be voided from the patient by blocking nerve impulses that would produce sphincter dyssynergia. An input device to allow an end user to select to apply the first type of stimulation or the second type of stimulation. Variations are also disclosed.
Eleven synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary "on-demand" voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.
Methods, pharmaceutical formulations, and kits are provided for using neurokinin 2 receptor agonists to effectuate voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing voiding of urine and defecation in mammals that do not have a voiding dysfunction such as, for example, in a person who is comatose and may void unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with voiding dysfunction control over when and where they void.
patents
